Новые горизонты в применении оксалиплатина (Элоксатин)


М.Р. Личиницер, Н.Н. Семенов

В статье приведен обзор литературных данных и опыт собственного клинического применения терапевтических схем с включением (Элоксатина) при злокачественных новообразованиях различной локализации (колоректальный рак, рак желудка, рак яичников и др.). Препарат характеризуется высокой эффективностью и низкой токсичностью, обладает синергизмом с другими цитостатиками и "таргетными" средствами. При применении оксалиплатина наблюдается увеличение периода времени до прогрессирования заболевания, улучшаются показатели выживаемости. Существуют методы премедикации, снижающие периферическую нейротоксичность препарата, что позволяет улучшить переносимость проводимой терапии. Оксалиплатин рассматривается как одно из наиболее перспективных противоопухолевых средств в плане научного изучения и практического использования.

Литература






  1. Семенов Н.Н., Перевощиков А.А., Личиницер М.Р. Новые возможности применения Оксалиплатина (Элоксатина) в лечении злокачественных опухолей // Фарматека. 2002. № 12. С. 40–44.
  2. Grothey A, et al. Randomize phase II trial of Capecitabine plus irinotecan (CapIri) and capecitabine plus oxaliplatin (CapOx) as first line therapy in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 2003, abst. 1022.
  3. Grothey A, et al. Capecitabine/irinotecan (CapIri) and capecitabine/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: Results of a randomized phase II study. Proc Am Soc Clin Oncol 2004, abst. 3534.
  4. Haller DG. Final results of a randomized phase III trial comparing irinotecan+oxaliplatin (IROX) to irinotecan monotherapy in patients with metastatic colorectal cancer (MCRC) previously treated with fluoropyrimidines Ann Oncol 2004;15(suppl. 3):263O.
  5. van Cutsem E, et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Ann Oncol 2004;15(suppl. 3):339P.
  6. Meyerhardt JA, et al. Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2004, аbst. 3580.
  7. Steward W, et al..Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer Ann Oncol 2004;15(suppl. 3):348P.
  8. Andre T, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343–51.
  9. Pan H-M, et al. A phase II study of oxaliplatin with ELF regimen in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 2004, аbst. 4206.
  10. Zhang WM, et al. Clinical results of advanced gastric cancer patients treated with oxaliplatin-containing regimen Ai Zheng 2003;22:1346–48.
  11. Chacуn JI, et al. Oxaliplatin (Ox) and raltitrexed (Ral) as first line treatment for locally advanced and metastatic gastric adenocarcinoma: Results of an ONCOPAZ phase II trial (OPHA 0141). Proc Am Soc Clin Oncol 2004, аbstr. 4213.
  12. Souglakos J, et al. Combination of Irinotecan (CPT-11) plus Oxaliplatin (L-OHP) as first line treatment in locally advanced or metastatic gastric cancer: a multicenter phase II trial. Ann Oncol 2004;15:1204–9.
  13. Santini D, et al. Weekly oxaliplatin, fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer (AGC). Proc Am Soc Clin Oncol 2004, Abst. 4237.
  14. Al-Batran SE, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004:15;22:658–63.
  15. Sumpter KA, et al. Randomised, multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: Confirmation of dose escalation. Proc Am Soc Clin Oncol 2003;22:257, abstr 1031.
  16. Louvet C, et al. GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non resectable pancreatic adenocarcinoma: Final results of the GERCOR /GISCAD Intergroup Phase III. Proc Am Soc Clin Oncol 2004, abstr. 4008.
  17. Van Laethem L, et al. Gemcitabine and oxaliplatine (GEMOX) in gemcitabine-refractory advanced pancreatic cancer: A phase II study. Proc Am Soc Clin Oncol 2004, аbst. 4119.
  18. Ferrandina G, et al. Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent platinum-sensitive ovarian cancer. Proc Am Soc Clin Oncol 2004, аbst. 5078.
  19. Mavroudis D, et al. A phase I-II trial of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with advanced ovarian cancer (AOC). Proc Am Soc Clin Oncol 2004, аbstr. 5020.
  20. Pectasides D, et al. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: A phase II study. Gynecol Oncol 2004;95:165–72.
  21. Buosi R, et al. Preliminary results of phase II trial with combination of gemcitabine and oxaliplatin in elderly patients with advanced NSCLC. Proc Am Soc Clin Oncol 2004, аbst. 7348.
  22. Winegarden JD et al. A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2004;15:915–20.
  23. Pectasides D, et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study. Eur Urol 2004;46:216–21.
  24. Schutte W, et al. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer 2003;4:294–7.
  25. Gebbia N, et al. A phase 2 study of oxaliplatin (O) – capecitabine (C) chemotherapy in metastatic breast cancer (MBC) patients pretreated with anthracyclines and taxanes. Proc Am Soc Clin Oncol 2004, аbst. 705.
  26. Gamelin L, et al. Prevention of Oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving Oxaliplatin combined with 0-Fluorouracil and Leucovorin for advanced colorectal cancer. Clin Cancer Res 2004, р. 10.



Бионика Медиа